(CercleFinance.com) – The American indices end the session in the green this Wednesday evening on Wall Street, the day after a closing of the equity indices in dispersed order with the questions raised by the Omicron variant. The S & P500 and the Dow Jones are up 0.14% and 0.25% while the Nasdaq-100 is close to equilibrium (-0.1%).
‘Despite a South African study showing its lesser dangerousness and the halving of the isolation period, the new strain is causing flight cancellations, store closures and new restrictive measures in many countries,’ says Kiplink.
‘Investors are still looking to better assess the impact of the Omicron variant on the economy. The cancellations of flights and the restrictions put in place by governments to stem its spread indeed call for caution, ‘he continues.
In today’s statistics, the United States’ trade deficit in goods jumped 17.5% to $ 97.8 billion in November, according to an advanced estimate, a sequential jump that reflects both a decline in exports and above all an increase in imports.
In the news of values, Apple would have issued shares to give them to some of its engineers so as to avoid their departures from certain competing technology groups like Meta Platforms, according to Bloomberg.
In an interview with Nikkei Asia, PayPal CEO Dan Schulman says he wants to reach at least $ 50 billion in revenue by 2025 and for that, make a new acquisition in Japan, in addition to that of Paidy announced last September. .
Victoria’s Secret, a women’s lingerie and cosmetics brand resulting from the recent spin-off of L Brands, announces that it has entered into an accelerated share buyback agreement with Goldman Sachs for an amount of $ 250 million.
Johnson & Johnson pharmaceutical companies Janssen announce that they have applied to the United States Food and Drug Administration (FDA) via a biological license application (BLA) to obtain approval for teclistamab, an experimental bispecific antibody ready for use. use, for the treatment of patients with relapsed or refractory multiple myeloma (R / R).
AstraZeneca announced today that it has entered into a global development and commercialization agreement with Ionis Pharmaceuticals for eplontersen, formerly known as IONIS-TTR-LRX.
AstraZeneca will initially pay Ionis $ 200 million, with additional conditional payments of up to $ 485 million following regulatory approvals. The Anglo-Swedish lab will also pay up to $ 2.9 billion in sales-related milestones based on sales thresholds between $ 500 million and $ 6 billion, plus various royalties.
Copyright (c) 2021 CercleFinance.com. All rights reserved.